Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Barclays lifted its price target on Johnson & Johnson (NYSE:JNJ) to $197 from $176 on December 2 while maintaining an ...
Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim ...
Johnson & Johnson's planned $3 billion acquisition of Halda Therapeutics is one of the largest deals for a CT-based biotech ...
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $145.0 to $255.0 for Johnson & Johnson over the last 3 months.
The FDA’s Circulatory System Devices Panel voted not to recommend approving use of an interatrial shunt to improve heart failure symptoms and prognosis.In a 0-15 vote, the committee determined risk ...
Bristol Myers Squibb has struggled over the past few years due to patent cliffs. And to make matters worse, it will soon face ...
Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, ...
Taylor Brooks has just announced that Perk Imaging has signed a lease for Shevlin Crossing Building B, introducing an ...
Co-led by SemperVirens Venture Capital and Next Ventures, with participation by Sanofi Ventures, Lux Capital, Civilization ...
Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback